Advanced Search
DSpace@MIT

Evaluating future biopharmaceutical inspection needs, infrastructure capability gaps, and technology development strategies

Research and Teaching Output of the MIT Community

Show simple item record

dc.contributor.advisor Roy Welsch and Douglas Hart. en_US
dc.contributor.author Hollander, Marnix E. (Marnix English) en_US
dc.contributor.other Leaders for Global Operations Program. en_US
dc.date.accessioned 2012-11-19T19:18:28Z
dc.date.available 2012-11-19T19:18:28Z
dc.date.copyright 2012 en_US
dc.date.issued 2012 en_US
dc.identifier.uri http://hdl.handle.net/1721.1/74919
dc.description Thesis (S.M.)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering; and, (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; in conjunction with the Leaders for Global Operations Program at MIT, 2012. en_US
dc.description Cataloged from PDF version of thesis. Page 70 blank. en_US
dc.description Includes bibliographical references (p. 61-62). en_US
dc.description.abstract The biotechnology industry is undergoing a paradigm shift in the properties of the manufactured drug product. As therapeutic protein formulations change from agonist to antagonist methods of action, the concentration of proteins in each dose increased by orders of magnitude, and with it, the challenge of producing and inspecting the product. Current inspection technologies meet the requirements to properly inspect the existing drug product portfolio, but as new pipeline drugs enter commercial manufacturing, inspection will become a pressing issue from operational efficiency, compliance, and quality standpoints. It is known that the properties of some of these pipeline products render them "uninspectable" by currently installed Automatic Visual Inspection Machines (AVIMs) but the scale and scope of the challenge is not well defined currently. The process and approach outlined in this research focuses on distilling large datasets of future product forecasts together with product attributes and infrastructure capability to generate a quantitative understanding of the future challenge. Through this research, product attributes critical to inspection such as viscosity, presentation, and protein aggregation, are identified for each commercial and pipeline drug product. These attributes are paired with production forecasts to generate attribute focused inspection requirements through 2020, which are then mapped against current capabilities. Gaps identified between requirements and current infrastructure capabilities are determined and the scale quantified. These capability gaps are then segmented by potential solutions, complexity of solutions, and cost of inaction in order to give Amgen the best foresight into future decisions and investments. Based on the gaps identified and near term engineering challenges, several solutions are developed, proposed, and tested throughout the internship. These include the use of Surface Acoustic Waves (SAW) to agitate heavy particles into suspension through acoustic streaming, enhanced lighting and imaging techniques to better identify particles, and segmented machine vision algorithms. These approaches are part of a larger portfolio of technical solutions which must be developed to address future product attributes which render current inspection processes ineffective. en_US
dc.description.statementofresponsibility by Marnix E. Hollander. en_US
dc.format.extent 70 p. en_US
dc.language.iso eng en_US
dc.publisher Massachusetts Institute of Technology en_US
dc.rights M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. en_US
dc.rights.uri http://dspace.mit.edu/handle/1721.1/7582 en_US
dc.subject Mechanical Engineering. en_US
dc.subject Sloan School of Management. en_US
dc.subject Leaders for Global Operations Program. en_US
dc.title Evaluating future biopharmaceutical inspection needs, infrastructure capability gaps, and technology development strategies en_US
dc.title.alternative Evaluating future biopharmaceutical product inspection needs, capability gaps, and technology investment strategies en_US
dc.type Thesis en_US
dc.description.degree M.B.A. en_US
dc.description.degree S.M. en_US
dc.contributor.department Massachusetts Institute of Technology. Dept. of Mechanical Engineering. en_US
dc.contributor.department Sloan School of Management. en_US
dc.contributor.department Leaders for Global Operations Program. en_US
dc.identifier.oclc 815725165 en_US


Files in this item

Name Size Format Description
815725165.pdf 10.39Mb PDF Preview, non-printable (open to all)
815725165-MIT.pdf 10.38Mb PDF Full printable version (MIT only)

This item appears in the following Collection(s)

Show simple item record

MIT-Mirage